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Abstract
Background/Objective: Reverse transcription quantitative real-time PCR (RT-qPCR) is widely used in microRNA (miRNA)
expression studies on cancer. To compensate for the analytical variability produced by the multiple steps of the method,
relative quantification of the measured miRNAs is required, which is based on normalization to endogenous reference
genes. No study has been performed so far on reference miRNAs for normalization of miRNA expression in urothelial
carcinoma. The aim of this study was to identify suitable reference miRNAs for miRNA expression studies by RT-qPCR in
urothelial carcinoma.
Methods: Candidate reference miRNAs were selected from 24 urothelial carcinoma and normal bladder tissue samples by
miRNA microarrays. The usefulness of these candidate reference miRNAs together with the commonly for normalization
purposes used small nuclear RNAs RNU6B, RNU48, and Z30 were thereafter validated by RT-qPCR in 58 tissue samples and
analyzed by the algorithms geNorm, NormFinder, and BestKeeper.
Principal Findings: Based on the miRNA microarray data, a total of 16 miRNAs were identified as putative reference genes.
After validation by RT-qPCR, miR-101, miR-125a-5p, miR-148b, miR-151-5p, miR-181a, miR-181b, miR-29c, miR-324-3p, miR-
424, miR-874, RNU6B, RNU48, and Z30 were used for geNorm, NormFinder, and BestKeeper analyses that gave different
combinations of recommended reference genes for normalization.
Conclusions: The present study provided the first systematic analysis for identifying suitable reference miRNAs for miRNA
expression studies of urothelial carcinoma by RT-qPCR. Different combinations of reference genes resulted in reliable
expression data for both strongly and less strongly altered miRNAs. Notably, RNU6B, which is the most frequently used
reference gene for miRNA studies, gave inaccurate normalization. The combination of four (miR-101, miR-125a-5p, miR-
148b, and miR-151-5p) or three (miR-148b, miR-181b, and miR-874,) reference miRNAs is recommended for normalization.
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Introduction
MicroRNAs (miRNAs) belong to a class of small noncoding
RNAs of 19 to 24 nucleotides that are known to regulate signaling
pathways for various cell functions. Not surprisingly, changes in
miRNA expression have been associated with several diseases,
including cancer [1,2]. It has been shown that different tumors
have specific miRNA expression profiles and that miRNA profiles
correlate with patient diagnosis, prognosis, and responses to
treatment [3]. Thus, analyzing the differential expression of the
microRNAome [4], defined as the entirety of all miRNAs in a cell,
is of scientific and practical significance.
Several methods such as bead-based flow cytometry, microarray,
deepsequencing,andreal-timequantitativePCR(RT-qPCR)allow
fast,high-throughput,andsensitiveprofilingofmiRNAs.RT-qPCR
produces specific, sensitive, and reproducible quantification of
nucleic acids. To overcome experimental variations in RT-qPCR
analyses (RNA isolation, cDNA synthesis, PCR runs), relative
quantification of miRNAs of interest based on the normalization to
reference genes is the approach of choice to prevent errors within a
dataset [5]. This approach complies with normalization procedures
used in mRNA expression studies and is summarized in the recent
MIQE guidelines [6]. Suitable reference genes should be expressed
constitutively and be independent of biological changes, diseases or
treatments. The use of multiple rather than single reference genes
has been recommended for RT-qPCR data normalization [7,8].
The computional programs geNorm [9] and NormFinder [10] are
based on this principle. These toolsallow identifying the moststable
reference genes from a panel of putative reference genes for
normalization. Moreover, several studies in addition to our own
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genes in the relative quantification of gene expression can result in
biased expression profiles [11–13]. As there are no universal
referencegenes[14,15],itisstronglyrecommendedthatresearchers
test for the most suitable reference genes specific to the tissues and
experimental conditions used.
Because of our general interest on miRNAomes in urological
tumors and the increasing incidence of urothelial cancer [16], we
performed a literature search in PubMed. The MeSH term
‘‘microRNAs’’ was combined with the search string [‘‘micro-
RNAs’’ OR ‘‘microRNA’’ OR ‘‘miRNA’’ OR ‘‘miRNAs’’] and in
combination with the MeSH term ‘‘urinary bladder neoplasms’’.
Fifty-eight articles published until May 2012 were identified, of
which 27 investigated miRNA expression. Specifically, 20
publications reported miRNA expression by RT-qPCR and used
small nuclear, nucleolar or ribosomal RNAs as well as mRNAs for
normalization, namely RNU6B (15 times) [17–31], RNU48 (6
times) [17,18,32–35], RNU43 (1 time) [30], RNU44 (1 time) [18],
beta-actin (1 time) [36], and 18srRNA (1 time) [32] without
confirming their validity for normalization. Thus, no systematic
study has been performed to identify suitable miRNA reference
genes in urothelial carcinoma while corresponding studies have
been performed for other cancer entities, including urological
tumors [13,37–40].
Bladder cancer is the fourth most common cancer in Western
industrialized countries [16]. Approximately 90% of all urothelial
neoplasms are classified as urothelial carcinoma. Although surgical
techniquesandtreatmentshaveimprovedovertime,bladdercancer
isstillacommoncancerwithahighmortality.Todate,mechanisms
of urothelial carcinogenesis have not been fully elucidated.
However, miRNA expression patterns have been linked to clinical
outcomes in urothelial carcinoma [18,24]. Therefore, single
miRNA biomarkers or biomarker signatures of multiple miRNAs
may improve risk stratification of patients and may supplement the
histological diagnosis of urological tumors including bladder cancer
[24,41–43]. In addition, miRNAs and their regulated genes
represent interesting drug targets because miRNAs can influence
the expressionofmultiple genesand therebyaffect numerouspoints
in disease pathways [22,44–46]. The significance of miRNAs in the
regulation of signal transduction in bladder cancer was recently
summarized [47]. Improved knowledge in this field will contribute
to enhanced prognosis and selection of treatment strategies.
However, as mentioned above, accurate quantification of miRNA
expression by RT-qPCR and thus reliable expression data require
proper normalization strategies. Computer programs based on
various algorithms including geNorm [9], NormFinder [10], and
BestKeeper [48] have been developed to rank putative reference
genes according to their expression stability and indicate the best
reference gene or combination of reference genes for accurate
normalization.
In the present study, we aimed to systematically identify suitable
reference genes for normalizing RT-qPCR assays of miRNA
expression in urothelial carcinoma tissue. Using miRNA micro-
array analyses, we first identified invariant miRNAs that showed
stable expression in both nonmalignant and malignant bladder
tissue samples as candidate reference miRNAs. RT-qPCR
analyses were subsequently performed for validating these
miRNAs from the microarray experiments and the above
mentioned small RNAs RNU6B, RNU48, and Z30 as putative
reference genes. Appropriate reference miRNAs were identified by
geNorm, NormFinder, and BestKeeper, and the results of
unsuitable normalization are illustrated with invalid normalizers.
Materials and Methods
Patients and Tissue Samples
All bladder cancer patients went through radical cystectomy or
transurethral resection at the University Hospital Charite ´ in Berlin
between 2008 and 2009 and gave written informed consent for the
use of representative tissue specimens for research purposes. The
study was approved by the Ethic Committee of the University
Hospital Charite ´ (File: EA1/153/07). The samples were collected
immediately after surgery in liquid nitrogen and stored at 280uC
until further analysis. Tumor staging was performed in conformity
with the International Union Against Cancer [49] and histological
grading in accordance with the WHO/ISUP criteria of 2004 [50].
In total, 58 urothelial samples were included in this study.
Seventeen samples were from nonmalignant bladder tissue (15
male, 2 female patients; median age 68, range 47–80 years), 20
samples were from low-grade papillary urothelial carcinoma (18
male, 2 female patients; median age 68, range 50–86 years), and
21 samples were from high-grade tumors (14 male, 7 female
patients; median age 73, range 48–82 years).
Isolation of RNA and Characterization of Quantity and
Quality
Frozen histologic sections were prepared, stained with hema-
toxylin/eosin, and examined by uropathologists (A.E., E.K.). Only
tissue specimens with more than 80% tumor cells were included in
the study as tumor samples. Tissue cryotome sections (approxi-
mately 20–30 mg of tissue, wet weight) were treated with 350 mlo f
lysis buffer and total RNA including miRNAs was isolated using
the miRNeasy Mini Kit (Qiagen, Hilden, Germany) with 30 to
50 ml of elution buffer according to the manufacturer’s protocol.
An additional DNase I digestion step on the RNA binding silica
gel membrane of the spin column was performed. RNA
concentration and the 260 nm to 280 nm absorbance ratios were
measured on the NanoDrop 1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA). The quality of isolated
RNA was determined by the RNA integrity number (RIN) with a
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA).
Only samples with RIN values .5 were used. The RNA samples
(medians: 693 ng/ml; 830 ng/mg tissue) isolated from nonmalig-
nant as well as from low-grade and high-grade tumor tissue
samples showed comparable median 260/280 absorbance ratios
(2.02, 2.03, and 2.03) and RIN values (6.7, 5.9, and 6.3; Kruskal-
Wallis test, P=0.171).
Microarray-based miRNA Analysis
Microarray analyses of eight samples each from nonmalignant
tissue and low and high grade tumor specimens were performed.
One-color hybridizations on human catalog 8-plex 15 K micro-
RNA microarrays (AMADID 019118) from Agilent encoding
probes for 723 human and 76 viral microRNAs from the Sanger
database v10.1 were used. All reaction steps were carried out as
previously described in detail [51]. After hybridization, micro-
arrays were washed, scanned, and processed according to the
supplier’s protocol. The raw data were normalized using Gene-
spring GX11 Software (Agilent) with default parameters (threshold
raw signal to 1.0, percent shift to 90th percentile as normalization
algorithm and no baseline transformation). All microarray data
have been deposited in the NCBI GEO database with accession
number GSE36121. Further data analysis is described in the
Results section.
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RT-qPCR analyses of miRNAs were carried out with TaqMan
microRNA assays (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer’s protocol and the MIQE
guidelines [6] (Table S1) as previously described [13]. The reverse
transcription of miRNAs from total RNA (10 ng) was performed
with miRNA-specific stem-loop primers, 10 nmol dNTP mix,
2.6 U of RNase Inhibitor, 33.5 U of MultiScribe RT enzyme, and
1 6RT Buffer (Applied Biosystems). The generated cDNAs were
stored at 20uC until analysis. The qPCR measurements were
executed in white 96-well PCR plates (cat.no. 04729692001 with
sealing foils) with a 10 ml of final volume containing 1 ml of RNA-
specific cDNA, 16 TaqMan Universal PCR Master Mix No
AmpErase UNG, and gene-specific TaqMan MiRNA real-time
PCR assay solution on the Light Cycler 480 Instrument (Roche
Diagnostics GmbH, Mannheim, Germany; software version 1.5.0)
(Table S2). The reaction was performed at 95uC for 10 min,
followed by 45 cycles of 95uC for 15 s, and 60uC for 60 s. All
samples were measured in triplicate; each PCR run included a no-
template control and two inter-plate calibrators. All no-template
controls were negative. To assess the specific amplification
efficiencies, we created calibration curves from dilution series of
miRNA-specific cDNAs or small nuclear RNAs (Methods S1). The
efficiency was determined from the slope of the log regression plot
of Cq values versus log input of cDNA. Efficiencies were in the
range between 81% and 88%. All data were corrected to the PCR
efficiency and to the inter-run calibrators. For that purpose, the
software qBase
PLUS (Biogazelle NV, Zwijnaarde, Belgium) was
used, employing a generalized and universally applicable quanti-
fication model based on efficiency correction, error propagation,
and multiple reference gene normalization [52]. The intra-run
precision for the finally considered candidate reference miRNAs
miR-29c, miR-101, miR-125a-5p, miR-148b, miR-151-3p, miR-
151-5p, miR-181a, miR-181b, miR-324-3p, miR-424, and miR-
874 as well as the investigated small nuclear RNU6B, RNU48,
and Z30 ranged from 0.15% to 0.35% for mean Cq values
between 21.93 to 26.65. The between-run precision (n=42)
measured for the control miR-21 was found to be 1.62% (mean
Cq 6 standard deviation: 28.3560.46).
Data Analysis
Statistical analyses were performed using GraphPad Prism
Version 5.04 (GraphPad Software Inc., La Jolla, CA, USA). Non-
parametric tests (Mann-Whitney U test; Kruskal-Wallis test with
Dunn’s multiple comparison test) were used to analyze significant
differences between independent groups. The Spearman correla-
tion coefficients were applied to calculate the relationships
between the miRNAs as well as between the clinical variables
and the expression of candidate reference miRNAs. P values
,0.05 (two-tailed) were considered statistically significant.
The assessment of the putative reference genes for normaliza-
tion was evaluated by the computer programs geNorm [9] using
the improved version geNorm
Plus as an implementation of the
software qBase
PLUS (Biogazelle, Belgium) [52], NormFinder [10],
and BestKeeper [48].
Results
Selection of Candidate Reference miRNAs by Microarray
Analysis
To identify putative reference miRNAs in the miRNA
microarray data obtained from the eight samples of each tissue
group, the following criteria were used: (a) miRNAs had to be
detected in Genespring GX11 software as ‘‘present’’ in all
examined 24 samples to filter out signals that did not reach a
minimum of intensity, (b) the absolute fold change between the
nonmalignant and the two cancerous groups had to be lower than
1.2-times with (c) no significant differences (P.0.05) between the
groups. Based on the total of 723 human miRNA species located
on the Agilent microarray chip according to the miRBase version
10.1, we identified 101 miRNAs that were flagged as ‘‘present’’ in
all of the examined groups (Table S3). Eight of these miRNAs
showed absolute fold changes lower than 1.2-times and had no
significant differences between the groups (Table 1, indicated by
Table 1. Candidate reference miRNAs selected from
microarray analysis.
{
miRNA
&
ID according miRBase
version
# Selection criterion
1
hsa-miR-15a hsa-miR-15a (v10.1) R
hsa-miR-15a-5p (v18)
hsa-miR-20b hsa-miR-20b (v10.1) R
hsa-miR-20b-5p (v18)
hsa-miR-29c hsa-miR-29c (v10.1) R
hsa-miR-29c-3p(v18)
hsa-miR-101 hsa-miR-101 (v10.1) N
hsa-miR-101-3p (v18)
hsa-miR-107 hsa-miR-107 (v10.1) N
hsa-miR-107 (v18)
hsa-miR-125a-5p hsa-miR-125a-5p (v10.1) N
hsa-miR-125a-5p (v18)
hsa-miR-148b hsa-miR-148b (v10.1) R
hsa-miR-148b-3p (v18)
hsa-miR-151-3p hsa-miR-151-3p (v10.1) R
hsa-miR-151-3p (v18)
hsa-miR-151-5p hsa-miR-151-5p (v10.1) N
hsa-miR-151-5p (v18)
hsa-miR-181a hsa-miR-181a (v10.1) R
hsa-miR-181a-5p (v18)
hsa-miR-181b hsa-miR-181b (v10.1) R
hsa-miR-181b-5p (v18)
hsa-miR-324-3p hsa-miR-324-3p (v10.1) N
hsa-miR-324-3p (v18)
hsa-miR-424 hsa-miR-424 (v10.1) N
hsa-miR-424-5p (v18)
hsa-miR-513a-5p hsa-miR-513a-5p (v10.1) R
hsa-miR-513a-5p (v18)
hsa-miR-874 hsa-miR-874 (v10.1) N
hsa-miR-874 (v18)
hsa-miR-939 hsa-miR-939 (v10.1) N
hsa-miR-939 (v18)
{The TaqMan MicroRNA Assay ID, miRBase accession number, and the sequence
for each miRNA are compiled in Table S2.
&miRNAs marked in Italics were not included in further analyses because their
low expression level was beyond the dynamic range of the assay (.35Cq)
(further details see text).
#The miRNA ID from the miRBase version 10.1 and 18, respectively.
1Symbols ‘‘N’’ and ‘‘R’’ indicate the selection of the candidate reference miRNAs
based on normalized or raw microarray data as described in the text.
doi:10.1371/journal.pone.0039309.t001
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microarray data, we also used raw microarray expression data.
Thus, with the criteria mentioned above, we revealed a second set
of eight candidate reference miRNAs (Table 1, indicated by
symbol ‘‘R’’). Taking these sets together, 16 putative reference
miRNAs were included in further analyses (Table 1; Table S2).
Validation of Candidate Reference Genes by RT-qPCR
To increase the statistical power to find suitable reference
miRNAs, in addition to the 24 analyzed samples in the microarray
experiments, we included nine nonmalignant and 25 malignant
tissue samples as described in the section ‘‘Patients and tissue
samples’’ to validate the aforementioned 16 candidate reference
miRNAs in more detail by RT-qPCR. Furthermore, the set of
candidate reference miRNAs was extended by the small RNAs
RNU6B, RNU48, and Z30 that were commonly used for
expression normalization in the literature as stated in the
Introduction. First, to determine if reliable quantification of these
putative normalizers is feasible by RT-qPCR, three RNA pools
were prepared containing equal amounts of RNA from the
samples used in the microarray analysis. miR-15a, miR-20b, miR-
107, miR-513a-5p, and miR-939 showed Cq values .35 in the
pools and were excluded from further analyses because accurate
quantification would be questionable. By this preselection, 11
putative reference miRNAs (Table 1: miR-29c, miR-101, miR-
125a-5p, miR-148b, miR-151-3p, miR-151-5p, miR-181a, miR-
181b, miR-324-3p, miR-424, and miR-874) as well as RNU6B,
RNU48, and Z30 were further investigated and showed Cq values
ranging from 22 (RNU48) to 28 (miR-324-3p).
In the second step, all 14 reference candidates were separately
measured in the 58 samples (Figure 1). The expression levels
significantly differed for miR-29c (P=0.0012), miR-101
(P=0.0007), miR-125a-5p (P,0.0001), miR-151-5p (P,0.0001),
miR-324-3p (P,0.0001), and RNU6B (P=0.0101) between
nonmalignant and malignant samples. The remaining eight
miRNAs, namely miR-148b, miR-151-3p, miR-181a, miR-181b,
miR-424, miR-874, RNU48, and Z30, revealed no significant
differences between nonmalignant and malignant samples
(P.0.05). We followed the general recommendation of the
geNorm program and included all these putative reference
miRNAs and small RNAs in further analyses for reassessing their
potential contribution as normalizers. However, miR-151-3p was
excluded due to the fact that miR-151-3p and miR-151-5p are
mature miRNAs of the same pre-miRNA and miR-151-5p
exhibited higher expression in examined samples.
Association between the Candidate Reference miRNAs
and Clinical Variables
The correlation between the putative reference miRNAs and the
correlationofthesemiRNAswithage,sex,andtumorcharacteristics
were determined. Spearman rank correlations are summarized in
Table S4. Classifying miRNA pairs with coefficients $0.60 as co-
expressed, we identified this characteristic co-expression feature
among the four miRNAs miR-101, miR-125a-5p, miR-151-5p and
miR-324-3p as well as between miR-148 and miR-151-3p, and
between miR-181a and miR-181b. The correlation between miR-
101, miR-151-5p, and miR-324-3p was remarkable.
The expression of the 11 miRNAs and three small RNAs was
not associated with age (Spearman rank correlation from rS 20.23
to 0.177, P values from 0.083 to 0.974), sex (Mann-Whitney U
test, P values from 0.062 to 0.851), or tumor stage (Ta, T1, T2,
T3; Kruskal-Wallis test, P values from 0.092 to 0.826, except for
miR-29c, which had P=0.044). Differences in expression between
low-grade and high-grade tumors were found for miR-29c (down-
regulated, P=0.005), miR-874 (down-regulated, P=0.019), miR-
181a (up-regulated, P=0.031), and miR-181b (up-regulated,
P=0.0008), while all other miRNAs were not differentially
expressed (P values from 0.092 to 0.826).
Identification of Suitable Reference miRNAs using
geNorm, NormFinder, and BestKeeper
To identify suitable reference genes for the normalization of
miRNA expression, we applied the aforementioned three com-
puter programs geNorm, NormFinder, and BestKeeper. GeNorm,
an implementation of the new software qBase
PLUS, automatically
returns the average expression stability value M and the average
Figure 1. Expression of candidate reference genes in human nonmalignant and malignant bladder tissue samples. RT-qPCR analyses
were performed from 17 nonmalignant bladder tissue samples and 41 samples from low-grade and high-grade papillary urothelial carcinoma.
Expression levels of the candidate reference genes are given as arbitrary units. Boxes (blank, nonmalignant samples; black, malignant samples)
represent lower and upper quartiles with median as horizontal line; whiskers depict the 10 and 90 percentiles. Significances are illustrated as P values
of the Mann-Whitney U test.
doi:10.1371/journal.pone.0039309.g001
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genes. The highest M value indicates the gene with the least stable
expression. Figure 2A and Table 2 indicate the M values and the
resulting ranking order of all investigated candidate reference
miRNAs and small RNAs based on expression stability. miR-181a
(M=1.511) showed the highest M value, whereas miR-151-5p
(M=0.622) and miR-125a-5p (M=0.663) showed the lowest M
values. Consequently, miR-181a had the least stable expression
while miR-125a-5p and miR-151-5p had the most stable
expression. Additionally, geNorm calculates a normalization factor
(VNF value), which is a criterion for the optimum number of
reference genes (Figure 2B). The program recommends VNF
values less than 0.15 for proper normalization. When this cut-off
value is achieved, it is not necessary to include any additional
reference genes. As illustrated in Figure 2B, the four miRNAs
miR-101, miR-148b, miR-125a-5p, and miR-151-5p (VNF value
0.14) were recommended as an optimum reference miRNA set for
normalization; the best combination of two reference miRNAs was
miR-125a-5p and miR-151-5p, and the best single reference
miRNA was miR-151-5p. After excluding the potentially dereg-
ulated reference miRNAs mentioned above, geNorm analysis was
repeated. However, under these conditions, geNorm calculated a
VNF value .0.15 and therefore did not recommend a normali-
zation set.
Similar to geNorm, NormFinder identified genes with the
lowest M values as the most stably expressed reference targets
(Table 2). NormFinder ranked the four best reference genes for
normalization as miR-148, miR-874, miR-181b, and Z30. Z30
and miR-125a-5p were recommended as the best combination,
and miR-148b was recommended as the best single normalizer
(Table 2).
BestKeeper considers all genes in all observed groups. First,
BestKeeper determines the geometric mean and coefficient of
variance. Genes with a standard deviation greater than 1 were
assumed to be inconsistent. In the second step, the inter-gene
relationships were examined by pairwise correlation analysis. This
calculation is used to determine whether the gene expression
exhibits a similar behavior. Candidate reference genes that highly
correlate with each other are included in the BestKeeper-Index
calculation. The program provides only an analysis of ten
candidate reference genes simultaneously. Therefore, we excluded
the reference targets with the lowest M values as determined by
geNorm (miR-181a) and NormFinder (miR-424) and also
excluded miR-29c (rank 9 by geNorm; rank 11 by NormFinder).
Under these conditions, BestKeeper ranked RNU48 as the best
reference gene, followed by miR-874, miR-151-5p, and Z30.
The comparison of the summarized data in Table 2 shows that
the results provided by NormFinder and BestKeeper displayed
slight differences from the geNorm analysis but did have some
overlap. While geNorm recommended miR-101, miR-125a-5p,
miR-148b, and miR-151-5p for proper normalization, NormFin-
der indicated miR-148b as the best reference miRNA and miR-
125a-5p as a part of the best combination. Additionally, Best-
Keeper identified miR-151-5p within the four most stably
expressed miRNAs. As stated in the Introduction, the small
nucleolar RNU6B is commonly used for miRNA expression
normalization and in our study was ranked 10
th by geNorm, 12
th
by NormFinder, and 9
th by BestKeeper (Table 2). Thus, RNU6B
seems to be a rather inappropriate reference gene for the miRNA
expression normalization in studies on bladder cancer.
Influence of Reference miRNA Selection on the Accuracy
of Relative Quantification
To illustrate the impact of reference gene selection on miRNA
expression analysis, we applied different normalization strategies
for the relative quantification of miR-200a and miR-20a
(Figure 3A–B). A preliminary evaluation of the miRNA micro-
array data showed a strong up-regulation of miR-200a (fold
change 22.1) and a less robust, but significant up-regulation of
miR-20a (fold change 2.78) in the tumor samples compared to the
nonmalignant tissue samples. Different normalization approaches
Figure 2. geNorm analysis of RT-qPCR-based candidate
reference genes. (A) The geNorm analysis shows the calculation of
the average expression stability value M of all candidate reference
genes determined by RT-qPCR. Genes with the highest M value have
the least stable expression, while the genes with the lowest M value
have the most stable expression. The x-axis presents the ranking of
reference genes in order of increasing stability from left to the right. (B)
Calculation of the optimal number of reference genes for normalization.
geNorm calculates a normalization factor assessing the optimal number
of reference genes for generating that factor. The normalization factor
is calculated from at least two genes taking into account the variable V
as the average pairwise variation (VNF) between two sequential
normalization factors. The thin broken line illustrates the cut-off value
VNF ,0.15. In this experiment, the optimal number of reference genes
was four (V4/5). geNorm shows the variation of the normalization factor
of four genes as the best combination (miR-101, miR-148b; miR-125a-
5p, and miR-151-5p) in relation to five genes as shown in (A) and in the
following order. All the results are presented according to the output
files of the geNorm program.
doi:10.1371/journal.pone.0039309.g002
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der, and BestKeeper as described above. As shown in Figure 3, we
normalized the expression of miR-200a and miR-20a using the
geNorm recommended reference miRNAs as follows: (a) the
combination of four reference miRNAs that were suggested to be
necessary for reliable normalization (geometric mean of miR-101,
miR-125a-5p, miR-148b, and miR-151-5p; Table 2); (b) the three
best ranked miRNAs according to their M values (miR-125a-5p,
miR-148b, and miR-151-5p), and (c) the best combination of two
miRNAs (miR-125a-5p and miR-151-5p). The NormFinder
recommended approaches were the following: (d) the best two
reference gene combination (miR-125a-5p and Z30); (e) the three
best ranked reference miRNAs (miR-148b, miR-181b, and miR-
874), and (f) the best single miRNA miR-148b. Based on the
BestKeeper recommendation, we also used (g) the calculated best
single reference gene RNU48. In addition, we performed
normalization with (h) RNU6B, which was estimated by all three
programs to have low usefulness as a reference gene but is
frequently used in expression studies. Regardless of the normal-
ization approach, miR-200a was found to be up-regulated
(Figure 3A). However, the expression pattern of miR-20a was
different depending on the normalization approach (Figure 3B).
Using the reference miRNAs recommended by geNorm or
NormFinder, miR-20a appeared to be up-regulated in tumor
samples, whereas normalization with RNU6B or RNU48 as
recommended by BestKeeper did not show up-regulation of this
miRNA. Thus, although all reference miRNA suggestions by
geNorm and NormFinder were obviously suited to be appropriate
for normalization, we recommend the use of more than two
reference miRNAs preferring the use of four miRNAs (miR-101,
miR-148b, miR-125a-5p, and miR-151-5p) as recommended by
geNorm or the combination of three miRNAs (miR-148b, miR-
181b, and miR-874) suggested by NormFinder. The two-miRNA
combinations or single miRNAs should be cautiously considered
as alternative normalization approaches only if limited sample
material is available for analysis.
Discussion
The selection of suitable reference genes as normalizers for
relative quantification of mRNA and miRNA expression is
essential to avoid erroneous expression results and to improve
the comparability of gene expression data between different
studies. Different models such as the global mean normalization
[5], panels of miRNAs [37] or small RNAs [53] have been
suggested for the normalization of miRNA expression data.
D’haene et al. [54] recently reported that the side-by-side
comparison of small nuclear RNA normalization with global
mean normalization indicated that small nuclear RNAs are less
efficient in reducing the technical variation and do not reveal in
accurate expression differences. In addition, the recommended
global mean normalization method [5] that is also included in the
algorithm of the qBase
PLUS software requires a large number of
genes, for example in microarray, deep sequencing, bead-based or
TaqMan array card analyses. Thus, the global normalization
approach is not feasible in RT-qPCR studies because only a few
miRNAs are generally measured. In this case, the normalization of
miRNA RT-qPCR data with suitable miRNA reference markers
can be considered as the method of choice [55].
Studies to identify and validate suitable reference miRNAs have
been performed for several cancers [13,37–40]. As discussed in the
Introduction, it is therefore quite astonishing that no miRNA
expression studies in bladder cancer have used endogenous
miRNAs for normalization. Only nuclear, nucleolar, and
ribosomal RNAs as well as mRNAs have been used. However,
the different lengths of these RNAs compared to miRNAs result in
different physico-chemical properties with different isolation
efficiencies and degradation [56,57]. miRNAs are more stable
Table 2. Ranking of candidate reference miRNAs and small RNAs in human nonmalignant and malignant bladder tissues
according to their stability value using geNorm, NormFinder, and BestKeeper algorithms.
geNorm NormFinder BestKeeper
Gene name Stability value
& Rank Stability value
& Rank SD [±x-fold]
# Rank
miR-101 0.734 4 0.215 8 0.69 10
miR-125a-5p 0.663 2 0.192 6 0.62 5
miR-148b 0.693 3 0.086 1 0.65 8
miR-151-5p 0.622 1 0.230 9 0.60 3
miR-181a 1.511 13 0.209 7 –
miR-181b 0.959 9 0.155 3 0.62 6
miR-29c 0.863 7 0.246 10 –
miR-324-3p 0.76 5 0.291 11 0.64 7
miR-424 1.172 12 0.371 13 –
miR-874 0.824 6 0.102 2 0.53 2
RNU6B 1.001 10 0.349 12 0.67 9
RNU48 0.906 8 0.173 5 0.51 1
Z30 1.037 11 0.171 4 0.61 4
Best gene miR-151-5p miR-148b RNU48
Best combination miR-101, miR-125a-5p, miR-
148b, miR-151-5p
Z30, miR-125a-5p –
&High expression stability is indicated by low stability value.
#SD [6x-fold]: standard deviation of the absolute regulation coefficients. SD .1 can be considered inconsistent.
doi:10.1371/journal.pone.0039309.t002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39309Figure 3. Effects of different normalization approaches on the expression of miR-200a and miR-20a. The relative expression of (A) miR-
200a and (B) miR-20a as highly and moderately differentially expressed miRNAs, respectively was calculated using the following normalization
strategies recommended by geNorm (a–c), NormFinder (d–f), BestKeeper (g), and RNU6B (h). The geNorm approaches were: (a) the four-reference-
miRNA combination recommended as necessary number of reference miRNAs (miR-101, miR-125a-5p, miR-148b, miR-151-5p); (b) the three best
ranked miRNAs according to their M values (miR-125a-5p, miR-148b, and miR-151-5p) and (c) the best two-gene-reference combination (miR-125a-
5p, miR-151-5p). NormFinder normalization approaches were: (d) the best two reference gene combination (miR-125a-5p, Z30); (e) the three best
ranked reference genes (miR-148b, miR-181b, miR-874); (f) the best single miRNA, miR-148b. BestKeeper normalization approach was (g) RNU48; (j)
RNU6B as the most frequently recommended normalizer in bladder cancer studies. Values are given as arbitrary units; boxes (blank, nonmalignant
tissue; black, malignant tissue) represent lower and upper quartiles with medians as horizontal line; whiskers depict the 10–90 percentiles.
Significances are illustrated as P values of the Mann-Whitney U test.
doi:10.1371/journal.pone.0039309.g003
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be more accurately detected in tissues [57]. In addition, different
techniques of reverse transcription used for miRNAs and the other
RNAs make the latter less suitable for normalization. Further-
more, as previously shown for mRNAs, the tissue-specific
expression of miRNAs is also reflected in the behavior of putative
endogenous reference genes [14,15]. Thus, RT-qPCR-based
miRNA expression studies optimally require normalization by
reference miRNAs. Previous reports from our group have
demonstrated the importance of suitable reference miRNAs in
avoiding biased results in miRNA expression studies in other
urological tumors [13,39]. These data strongly support the need
for determining appropriate endogenous reference miRNAs to
allow stringent normalization of miRNA expression patterns in
urothelial carcinoma.
To the best of our knowledge, the present study is the first
systematic investigation of suitable normalizers for relative quanti-
fication of miRNA expression in bladder cancer. In this study, we
combined different strategies for identifying suitable reference
miRNAs. A four step approach was used. First, to obtain an
overview of the miRNAome in bladder cancer tissue, miRNA
microarray analyses for nonmalignant and malignant bladder
samples were performed to identify invariant miRNAs as stably-
expressed candidate reference miRNAs within the data set. Second,
these candidate reference miRNAs were validated by RT-qPCR, in
addition to RNU6B, RNU48, and Z30, the most frequently
reported reference genes for miRNA expression studies in bladder
cancer. Third, the statistical algorithms geNorm, NormFinder, and
BestKeeper were applied to identify the most useful endogenous
reference miRNAs for relative quantification. Finally, the impact of
different normalization approaches was illustrated for two deregu-
lated miRNAs inbladdercancer tissue to emphasize the importance
of an appropriate normalization approach.
The starting point of the present study was miRNA microarray
analysis. According to the criteria for the microarray data
evaluation and the measurability criterion for subsequent RT-
qPCR analysis (Cq values ,35), 11 invariant miRNAs were
identified to be putative reference miRNAs. Since miR-151-3p
and miR-151-5p derive from the same pre-miRNA and miR-151-
5p exhibited slightly higher expression in examined samples, we
included only miR-151-5p in further analysis. A data search in the
miRNA bladder cancer studies mentioned in the Introduction
showed that miR-29c, one of these 11 invariant, stably expressed
miRNAs, was found to be down-regulated in two microarray
studies [19,36]. Our subsequent RT-qPCR confirmed this
observation (Figure 1). Although we did not eliminate this miRNA
from the subsequent analysis for the validation of suitable
reference miRNAs through geNorm, NormFinder, and Best-
Keeper, miR-29c was never recommended as a reference miRNA
by one of these evaluation tools in our following analyses. This
finding also indicates the usefulness of the software packages in the
search for suitable reference genes.
The putative reference miRNAs identified by the microarray
analyses, except miR-151-3p as mentioned, were included with the
additional RNAs RNU6B, RNU48, and Z30 in the geNorm,
NormFinder, and BestKeeper analysis. Differences in expression
observed in the subsequent RT-qPCR measurements between
nonmalignant, low-grade, and high-grade tumor samples as well as
co-expressions of genes did not exclude candidate reference genes.
However, as comprehensively described in the Results section,
geNorm, NormFinder, and BestKeeper did not always recom-
mend the same reference miRNAs for normalization (Table 2).
The lack of agreement between geNorm and NormFinder results
has been described previously [15]. The reasons for these
differences in the ranking order of the putative reference miRNAs
might be due to the different calculation models on which the tools
are based. NormFinder is an ANOVA-based model, geNorm uses
a pairwise comparison model, and BestKeeper determines the
optimal reference genes by employing the pairwise correlation
analysis on all pairs of candidate reference genes. While the
geNorm approach is theoretically robust with regard to inter-
sample variations arising from sources such as differing RNA input
and quality, it has been shown to prefer co-regulated genes in the
selection as normalizers [10]. In this study, geNorm also
recommended co-regulated reference miRNAs (miR-101 with
miR-125a-5p, miR-151-5p) but miR-324-3p was never recom-
mended as normalizer despite its strong correlation with miR-101
and miR-151-5p.
The differences between the recommended reference miRNAs
by the three programs prompted us to validate their suitability in
clinical samples (Figure 3A–B). The importance of selecting
suitable reference genes for accurate miRNA expression data has
been shown not only in mRNA but also in miRNA expression
studies [13,37,39,40]. We tested the suitability of the different
approaches with miR-200a, a highly up-regulated miRNA, and
miR-20a, which is up-regulated less robustly (Figure 3A, B). The
results clearly demonstrated that RNUB6, which is the most
frequent normalizer used in previous miRNA expression studies in
bladder cancer, and RNU48, which was recommended by
BestKeeper, were unable to confirm the small expression changes,
e.g. for miR-20a. The poor quality of RNU6B as a reference gene
has already been reported in miRNA expression studies in renal
cell carcinoma and prostate cancer [13,58], where its altered
expression stability depended on the degradation of the RNA as
compared with miRNAs [13]. In contrast, all geNorm and
NormFinder recommendations for single and multiple reference
miRNA combinations proved to be suitable normalization
approaches in the present study for revealing not only strongly
but also less robustly deregulated miRNA expression levels
between nonmalignant and malignant urothelial tumor samples.
However, we recommend the combination of four (miR-101, miR-
125a-5p, miR-148b, and miR-151-5p) or three (miR-148b, miR-
181b, and miR-874) reference miRNAs. Although the normaliza-
tion with the best single (NormFinder) or the best two (geNorm)
reference miRNAs in our study gave comparable results to the
larger gene sets, the use of multiple reference miRNAs is critical in
achieving more reliable expression data [7–10].
In summary, the present study was the first systematic
investigation to identify suitable reference miRNAs in a transpar-
ent and comprehensive manner for the relative quantification of
the microRNAome in urothelial carcinoma. It was based on a
four-step approach with microarray analyses, RT-qPCR valida-
tion, reference miRNA selection through computer software, and
proof of principle with different miRNA expression levels. Starting
with 16 putative reference miRNAs from the microarray analysis
and three additional small RNAs from the literature, we validated
several combinations of reference miRNAs for miRNA expression
studies in bladder cancer. We believe that these are robust
methods that will allow future studies on the functional roles of
miRNAs as regulators in signal transduction and metabolic
pathways that are associated with small expression changes.
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